View in EDS

1510TiPThe GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors.

Saved in:
Bibliographic Details
Title: 1510TiPThe GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors.
Authors: Garralda, E1 (AUTHOR), Hoef, M van2 (AUTHOR), Ochsenreither, S3 (AUTHOR), Gianni, L4 (AUTHOR), Lorusso, D5 (AUTHOR), Fiedler, W6 (AUTHOR), Keilholz, U7 (AUTHOR), Klinghammer, K8 (AUTHOR), Dicke, C9 (AUTHOR), Kebenko, M9 (AUTHOR)
Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdy292.131